Phesgo and Tecentriq Performance and Approvals

2023 sales outlook Sales drivers¹ Pharma: Key products with strong growth and momentum from ongoing launches Diagnostics: Base business with solid growth COVID-19 sales for Diagnostics and Pharma expected to decline by roughly CHF 5bn AHR² sales expected to erode by roughly CHF 1.6bn 1 At Constant Exchange Rates (CER); 2 AHR=Avastin, Herceptin, Rituxan/MabThera Group sales growth¹ Low single digit decline Roche 14

View entire presentation